Rn for treatment of periocular fibrous connective tissue sarcomas in the horse.

This research article explores the use of Radium-222 (222Rn) in treating periocular fibrous connective tissue sarcomas in horses. The results indicated a high rate of success, with a 12-month nonrecurrence rate of 92%.

Introduction

This study revolves around the use of Radium-222 (222Rn), a radioactive isotope, in the treatment of periocular (surrounding the eye) fibrous connective tissue sarcomas in horses. Sarcomas are cancerous tumors that arise from transformed cells of mesenchymal (connective tissue) origin.

Methodology

• The research involved experimentation on 12 of such sarcomas found in 11 horses.
• 222Rn was administered to these tumors as a part of the treatment regimen.
• Post-therapy follow-ups were conducted on these horses for durations ranging from one year to six years in order to observe the results and possible recurrence of the sarcomas.

Findings

• The outcome after 12 months of therapy was extremely encouraging with a nonrecurrence rate of 92%. This indicates that the chances of the sarcomas recurring after undergoing 222Rn treatment were relatively low for this duration.
• Despite these impressive results, it was observed that two lesions did resurface after two years of treatment, and one did so after three years.
• Out of these recurring sarcomas, one of them did not show any signs of recurrence after being treated with 222Rn for the second time.

Conclusion

The overall findings suggest that using 222Rn for the treatment of periocular fibrous connective tissue sarcomas in horses yields high success rate. However, there exist chances of relapse after two to three years which need to be examined and addressed to improve the efficacy of this treatment method.